Circio Holding ASA Lubor Gaal is working as CFO and CBO for Circio, a key player in the emerging field of circRNA biology, a new therapeutic modality to make gene therapy cheaper and safer and to create novel protein (enzyme) replacement therapies. He currently is also Managing Director at BDLG, and has provided services from strategic consulting to licensing, asset divestures or M&A for various European biotech or pharma companies.
Lubor Gaal has over 25 years of experience in the pharmaceutical and biotechnology industry having worked in senior BD positions at Bayer (CNS and CV, NJ, US), Bristol-Myers Squibb (Head of Europe, Global CNS and Fibrosis, UK/USA) and Almirall (Global Head of BD & External Innovation, and member of the R&D management committee, Barcelona, Spain) and in senior management positions at biotech companies in France, Germany and Norway.
